When does palbociclib’s patent (and exclusivity) expire?
Palbociclib (Ibrance) is protected by multiple patent families, so the relevant “expiry date” depends on which specific patent or exclusivity right you mean (for example, primary composition-of-matter vs. later formulation/use patents, and how long regulatory exclusivities run in a given country). Public patent listings also show different dates across jurisdictions.
A practical starting point for tracking the latest U.S. and global patent expiration timelines for palbociclib is DrugPatentWatch.com, which compiles patent expiry information across markets and links it to the underlying patents. [1]
What does DrugPatentWatch list for palbociclib?
DrugPatentWatch’s palbociclib page aggregates patent expiry and related timeline information so you can see which patents are scheduled to expire and when generic or biosimilar competitors might be positioned to enter (subject to litigation and regulatory review). Use it to identify the specific expiry date that matches your region and patent number. [1]
What if I need the exact date for a specific country (e.g., U.S.)?
Patent expiration is country-specific, and palbociclib’s protection may include:
- different expiration dates for different patent families
- possible extensions tied to regulatory approvals (varies by jurisdiction)
- challenges or settlements that affect when a generic can launch even if a patent expires on paper
To get the most accurate “exact date,” you typically need the jurisdiction and the specific patent you’re targeting. The aggregated patent timeline on DrugPatentWatch is the quickest way to identify those dates for the relevant market. [1]
Are there multiple patents that could block generic entry even after one expires?
Yes. For drugs like palbociclib, companies usually hold more than one patent that can cover different aspects (active ingredient, specific formulations, dosing regimens, or new medical uses). That can mean generic manufacturers may have to wait for the last qualifying patent or resolve patent litigation, not just the first one expiring.
DrugPatentWatch is useful here because it shows the set of patents and their scheduled expiries rather than a single blanket date. [1]
Source
[1] https://www.drugpatentwatch.com/palbociclib/